Systemic Evaluation of Sjögren-Like Syndrome After Bone Marrow Transplantation in Man

Janin-Mercier, A; Devergié, A; Jp, Arrago; Brochériou, C; Lemarchand-Vénencie, F; Rain, J. D.; Gluckman, Éliane

doi:10.1097/00007890-198705000-00015

Cited by 31 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sjögren's-like disease can also develop in patients suffering from chronic GVHD following bone marrow transplantation (129). Comparison of minor salivary glands from these patients with glands from patients with Sjögren's syndrome revealed that relative contributions of different lymphocyte subsets to the infiltrates and expression of HLA-DR and adhesion molecules were different among the two groups (130).…”

Section: Murine Transplantation Chimeras (Gvhd)mentioning

confidence: 96%

Pathogenesis of Sjögren's Syndrome: Characteristics of Different Mouse Models for Autoimmune Exocrinopathy

Blokland¹,

Versnel²

2002

Clinical Immunology

View full text Add to dashboard Cite

Section: Murine Transplantation Chimeras (Gvhd)mentioning

confidence: 96%

Pathogenesis of Sjögren's Syndrome: Characteristics of Different Mouse Models for Autoimmune Exocrinopathy

Blokland¹,

Versnel²

2002

Clinical Immunology

View full text Add to dashboard Cite

“…Since the original descriptions, multiple reports of a Sjögren‐type syndrome in patients with GVHD have been published (Izutsu et al , 1983a,b; Janin‐Mercier et al , 1987; Lindahl et al , 1988; Rouquette‐Gally et al , 1988; Nakhleh et al , 1989). However, as different case definitions have been used to define GVHD salivary gland disease, it is difficult to determine the prevalence and time course of salivary gland pathology after transplant (Table 2).…”

Section: Salivary Gland Changesmentioning

confidence: 99%

Oral graft‐versus‐host disease

et al. 2008

View full text Add to dashboard Cite

OBJECTIVE: Graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality in patients receiving hematopoietic cell transplant. It is estimated that 40-70% of engrafted patients surviving the initial transplant eventually develop chronic GVHD (cGVHD), which can persist for months to years and require long-term management from multiple disciplines. This review describes the oral component of this transplant complication. DESIGN:The search related to GVHD patho-biology, salivary gland disease after hematopoietic cell transplant and treatments for oral GVHD encompassed literature from 1966 through 2008. Searches were limited to the MEDLINE/PubMed database and English language literature in peerreviewed journals. RESULTS:Our understanding of the patho-biology of oral cGVHD is based on studies of other affected tissues. It is difficult to determine the prevalence and incidence of salivary gland disease after transplant because there is no universally accepted case definition. In general, clinical trials for treatment of oral cGVHD have been too small to make strong recommendations for use in clinical practice. CONCLUSIONS:Larger well-designed clinical studies are needed to understand the patho-biology of oral cGVHD and determine best treatments for this disease.

show abstract

“…33 All these manifestations are closely related to cGVHD 34 that may lead in its most extensive forms to a Sjögrenlike syndrome. 35 The ocular manifestations include reduced tear flow, keratoconjunctivitis sicca, sterile conjunctivitis, corneal epithelial defects, and corneal ulceration.…”

Section: Ocular Complications Of the Anterior Segmentmentioning

confidence: 99%